[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuropathic-pain-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuropathic-pain-management":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100518325","tacs-for-neuropathic-pain-management-after-sci-100518325",false,"NCT06029075","tACS for Neuropathic Pain Management After SCI","tACS Brain Neuromodulation for Sensory and Motor Recovery After Neurological Impairments","Inclusion\u002Fexclusion criteria for SCI subjects\n\nInclusion criteria: A patient who\n\n1. has neuropathic pain after traumatic spinal cord injury or amputation or brain injury;\n2. has chronic pain, \\>3 months;\n3. is between 18 to 75 years of age;\n4. is stable on oral pain medications at least two weeks. Patients are allowed to continue their pain medications, i.e., no change in pain medications.\n\nNOTE: we plan to begin the study with the spinal cord injury (SCI) subject population as a cohort first, then expand to other subject populations\n\nExclusion criteria: Patients will be excluded if they\n\n1. are currently adjusting oral pain medications for their neuropathic pain;\n2. have pain, but not neuropathic, e.g., from inflammation at the incision wound of the residual limb or neuroma;\n3. have a pacemaker metal implants or supplemental oxygen;\n4. have amputation in their arm(s);\n5. fail to have a motor contraction in the arm muscles with TMS;\n6. are not able to follow commands, or to give consent;\n7. have asthma or other pulmonary disease;\n8. are not medically stable;\n9. have preexisting psychiatric disorders;\n10. alcohol or drug abuse.","ALL","18 Years","75 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall goal is to investigate the effectiveness of a novel intervention - transcranial alternating current stimulation (tACS) for neuropathic pain management in people after spinal cord injury.",[27],"Neuropathic Pain Management",[29,30],"tACS","Neuropathic Pain","RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-03","ACTUAL",{"date":37,"type":35},"2025-09-01",{"date":39,"type":21},"2028-03-31",{"name":41,"class":42},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100621960","beneficial-effects-of-supplementation-with-cronilief-palmitoylethanolamide-phospholipids-in-diabetic-subjects-with-neuropathic-pain-100621960","NCT07377409","Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.","Randomised, Placebo-controlled Study to Evaluate the Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids), in Addition to Standard Therapy, in Diabetic Subjects With Neuropathic Pain.","Inclusion Criteria:\n\n* Satisfactory metabolic compensation;\n* Presence of moderate symptoms of painful diabetic neuropathy as assessed by the LANSS questionnaire (score ≥12);\n* Taking antidiabetic drugs except insulin;\n* Subjects willing and able to comply with scheduled study visits, the treatment plan, and all procedures outlined in the study.\n\nExclusion Criteria:\n\n* Previous intolerance to a component of the nutraceuticals tested;\n* Individuals with type I diabetes;\n* Uncontrolled diabetes, severe cardiovascular and cerebrovascular diseases;\n* Severe neuropathic symptoms as indicated by the LANSS score;\n* Individuals undergoing insulin treatment;\n* Peripheral neuropathy due to diseases other than diabetes mellitus;\n* History of malignant neoplasm in the 5 years prior to enrolment in the study;\n* Serious neurological, psychological or psychiatric disorders;\n* Clinical signs or history of significant impairment of hepatic or renal function, peptic ulcer or coagulation disorders;\n* Any clinically relevant or unstable disease (e.g., active malignancies, immune system disorders) whose sequelae or treatments could contraindicate participation in the study or interfere with the study's evaluation parameters, in the investigator's judgement; Any disease that could significantly affect the study's outcome, including, but not limited to, chronic medical conditions, psychological disorders, or substance abuse;\n* Alcohol or drug abuse;\n* Women of childbearing age who do not use established contraceptive methods;\n* Pregnancy and breastfeeding.","65 Years",{"count":53,"type":21},70,[24],"This study aims to evaluate the potential benefit of an oral nutritional supplement based on CRONILIEF™ (Palmitoylethanolamide Phospholipids) in diabetic subjects with neuropathic pain, compared to a placebo.",[27,57,58],"Diabetic Neuropathies, Painful","Palmitoylethanolamide","NOT_YET_RECRUITING","2026-02-12",{"date":62,"type":35},"2026-02-17",{"date":64,"type":21},"2026-09-15",{"date":66,"type":21},"2027-01-15",{"name":68,"class":42},"Azienda di Servizi alla Persona di Pavia"]